<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neurologic manifestations of Sjögren's disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neurologic manifestations of Sjögren's disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neurologic manifestations of Sjögren's disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan N Baer, MD, MACR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shamik Bhattacharyya, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert I Fox, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Aminoff, MD, DSc</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H220565345"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sjögren's disease (SjD) is a chronic autoimmune inflammatory disease characterized by diminished lacrimal and salivary gland function. The clinical manifestations of SjD, however, include both exocrine gland involvement and extraglandular disease features, among which are an array of syndromes affecting the peripheral and central nervous systems (PNS and CNS) [<a href="#rid1">1-4</a>]. SjD occurs in a primary form not associated with other diseases and a secondary form that overlaps with other rheumatic conditions, most commonly rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).</p><p>The neurologic manifestations of SjD and their diagnosis and treatment will be reviewed here. The pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of both exocrine and the other extraglandular manifestations are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5620.html" rel="external">"Pathogenesis of Sjögren’s disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">"Treatment of dry eye in Sjögren’s disease: General principles and initial therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations"</a>.)</p><p></p><p class="headingAnchor" id="H465789934"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Many immune-related mechanisms have been postulated to underlie the neurologic disease of SjD; these vary, depending upon the neurologic syndrome, and generally parallel the pathogenic factors that appear to underlie the neurologic manifestations of systemic lupus erythematosus (SLE). These mechanisms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Small-vessel vasculopathy or frank vasculitis [<a href="#rid5">5-8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Dorsal root ganglionitis [<a href="#rid9">9,10</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cryoglobulinemia [<a href="#rid11">11</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Demyelination [<a href="#rid12">12</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Myelitis [<a href="#rid13">13</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Antineuronal antibodies [<a href="#rid14">14-16</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Antibody-mediated autonomic dysfunction [<a href="#rid17">17-19</a>]</p><p></p><p>The immunologic profile of SjD patients with neurologic involvement, compared with those without, varies depending upon the type of lesion. In a French study of 120 consecutive primary SjD patients, the 7 with sensorimotor neuropathy had a higher frequency of markers of monoclonal B-cell proliferation (mixed cryoglobulins, abnormal free light chain ratio, monoclonal gammopathy, and lymphoma) compared with those without peripheral neuropathy [<a href="#rid20">20</a>]. By contrast, the 20 with nonataxic sensory neuropathy had a lower frequency of antinuclear antibodies, Ro/SSA and La/SSB antibodies, rheumatoid factor, and hypergammaglobulinemia. In a Chinese study of 205 primary SjD patients, the titers of anti-Ro/SSA antibodies were significantly higher in the 40 patients with neurologic involvement compared with those without [<a href="#rid21">21</a>].</p><p>The pathophysiology in SjD of fatigue and mild cognitive dysfunction are not known but have been thought to be multifactorial, including pain [<a href="#rid22">22</a>], depression [<a href="#rid23">23</a>], immune-mediated endothelitis [<a href="#rid24">24-27</a>], and antibodies directed against N-methyl-D-aspartate receptor subtype NR2 (anti-NR2) and elevated heat shock protein 90a [<a href="#rid28">28,29</a>].</p><p>An analysis of these mechanisms is complicated by a complex differential diagnosis of the neurologic manifestations. As examples, the attribution of specific neurologic manifestations to SjD is confounded by a higher prevalence of neurodegenerative and cerebrovascular disease in the generally older-adult population affected by SjD, the frequent overlap of SjD with other systemic rheumatic diseases (such as SLE) that can also affect the nervous system, and the coincidence of SjD with autoimmune neurologic conditions, such as neuromyelitis optica spectrum disorder (NMOSD). As in any systemic rheumatic disease, infection and adverse effects of medications can have neurologic manifestations and must be included in the differential diagnosis.</p><p class="headingAnchor" id="H4021485554"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Estimates of the prevalence of neurologic involvement in SjD vary widely as a result of referral bias, disparate diagnostic criteria, differences in the thoroughness with which neurologic manifestations are sought, and whether these manifestations are clinically overt or asymptomatic [<a href="#rid30">30</a>]. Abnormal fatigue is present in the majority (prevalence estimated to be as high as two-thirds of patients) and significantly limits quality of life [<a href="#rid31">31,32</a>]. In a French cohort study of 392 patients with primary SjD, neurologic manifestations were present in 19 percent (peripheral in 16 percent and central in 4 percent) [<a href="#rid33">33</a>]. A Chinese cohort study of 205 patients with primary SjD reported similar findings [<a href="#rid21">21</a>]. In the French study, the annual incidence of new neurologic manifestations was 3.6 percent per year [<a href="#rid33">33</a>]. Neurologic manifestations may precede sicca symptoms in 33 to 93 percent of patients [<a href="#rid7">7,34,35</a>].</p><p>Peripheral neuropathy is likely the most common neurologic complication and was identified in 2 to 25 percent of three large primary SjD patient cohorts [<a href="#rid20">20,36,37</a>].</p><p>The frequency of central nervous system (CNS) involvement in SjD has long been controversial, and estimates vary widely [<a href="#rid30">30,38</a>]. In some studies, 20 to 25 percent of patients with primary SjD had CNS manifestations, ranging from diffuse symptoms to focal lesions that mimic multiple sclerosis [<a href="#rid6">6</a>]. By contrast, other groups have found a much lower prevalence of CNS disease in SjD [<a href="#rid5">5,39,40</a>]. There is also disagreement regarding whether cerebral white matter lesions on magnetic resonance imaging (MRI) are more prevalent in SjD patients [<a href="#rid41">41,42</a>] and whether they correlate with clinical manifestations of the disease or with age and cerebrovascular risk factors [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H2494431173"><span class="h1">PERIPHERAL NERVOUS SYSTEM DISORDERS</span><span class="headingEndMark"> — </span>SjD is associated with a complex array of peripheral nervous system (PNS) abnormalities [<a href="#rid7">7,44</a>]. Overlap may occur among the different forms of peripheral neuropathy. The relative frequency of these syndromes varies widely among case series.</p><p>Neuropathic symptoms precede the diagnosis of SjD in most patients, although many have other signs or symptoms of SjD. (See <a class="local">'Evaluation for Sjögren's disease in patients with neurologic disease'</a> below.)</p><p>Symptoms of neuropathy alone do not accurately identify neuropathy, which implies injury to peripheral nerves [<a href="#rid45">45</a>]. SjD patients may have fibromyalgia with neuropathic symptoms but without neuropathy. In addition, many patients will have subclinical disease (findings on electrodiagnostic studies) without symptoms [<a href="#rid46">46</a>]. The clinical diagnosis of neuropathy requires the combination of neuropathic symptoms with findings on examination (such as diminished reflexes, loss of sensation, or weakness) and supportive studies, such as electromyography/nerve conduction studies (EMG/NCS) and skin biopsy (intraepidermal nerve fiber density count).</p><p class="headingAnchor" id="H2841565336"><span class="h2">Axonal sensory and sensorimotor polyneuropathy</span><span class="headingEndMark"> — </span>Among the neuropathic syndromes in SjD, axonal sensory and sensorimotor polyneuropathies predominate, at least in some case series, with approximately equal frequency [<a href="#rid20">20,36,37</a>]. These neuropathies involve large myelinated fibers (which mediate proprioception, vibration, and touch, in addition to motor function), in contrast to the small-fiber sensory neuropathies (discussed below), which involve only unmyelinated and small myelinated fibers and mediate temperature and pain sensation. (See <a class="local">'Small-fiber neuropathy'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and findings on evaluation</strong> – Affected patients initially develop symptoms of a distal sensory neuropathy with distal paresthesia [<a href="#rid47">47</a>]. Examination demonstrates distal sensory deficits, including those of light touch, proprioception, and vibratory sensation. Weakness is generally mild when present, with involvement of toe flexors and extensors. Deep tendon reflexes may be diminished or absent, particularly in the Achilles tendon.</p><p></p><p class="bulletIndent1">In contrast to small-fiber sensory neuropathy, sensorimotor neuropathy is associated with more severe extraglandular disease, low C4 complement levels, and cryoglobulinemia [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Patients with symptoms and signs suggesting neuropathy generally undergo EMG/NCS to characterize the neuropathy. Nerve conduction velocities are relatively preserved, while sensory nerve action potentials (SNAPs) have reduced amplitude; compound muscle action potentials (CMAPs) may or may not be reduced [<a href="#rid48">48,49</a>].</p><p></p><p class="bulletIndent1">Other causes of axonal polyneuropathy should be excluded. (See  <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">"Overview of polyneuropathy", section on 'EMG with axonal physiology'</a>.)</p><p></p><p class="bulletIndent1">A subset of these patients have a vasculitic neuropathy such as that associated with cryoglobulinemia. Clues that a vasculitic neuropathy may be present in a patient with an apparent polyneuropathy include asymmetric involvement on examination and electrodiagnostic studies, rapid onset, or stepwise progression of the neurologic deficits. Epineural and perivascular lymphocytic infiltrates have been observed in nerve biopsies [<a href="#rid5">5,50,51</a>]. Patients with findings suspicious for a vasculitic neuropathy need an expedited evaluation, often including a combined nerve and muscle biopsy for definitive evidence of vessel inflammation [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">The axonal large-fiber neuropathies may coexist with a small-fiber sensory neuropathy, with diminution in intraepidermal nerve fiber density [<a href="#rid53">53</a>]. (See <a class="local">'Small-fiber neuropathy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment is predicated upon the severity and manifestations of the neuropathy and other systemic manifestations of the vasculitis (if present).</p><p></p><p class="bulletIndent1">For patients with predominantly sensory symptoms, the initial treatment is usually symptomatic, as described for small-fiber neuropathy [<a href="#rid47">47,54</a>]. (See <a class="local">'Small-fiber neuropathy'</a> below.)</p><p></p><p class="bulletIndent1">Patients with sensorimotor polyneuropathy and those who have an inadequate response to symptomatic therapy may be treated with immunosuppressive agents, such as a tapering course of glucocorticoids (starting at 0.5 to 1 mg/kg/day), coupled with a conventional synthetic disease-modifying antirheumatic drug (DMARD; eg, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> 1 to 2 mg/kg/day). However, the clinical response is often disappointing [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1">For vasculitic neuropathy such as that associated with cryoglobulinemia, more intensive immunosuppression is required, generally with glucocorticoids and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>. We also treat patients with a severe and progressive sensorimotor neuropathy, especially with motor involvement, even when the presence of cryoglobulins or vasculitis has not been confirmed. The treatment response appears to be better in patients with necrotizing vasculitis or cryoglobulins; however, clinical relapse is common [<a href="#rid52">52,55</a>].</p><p></p><p class="headingAnchor" id="H2668898378"><span class="h2">Small-fiber neuropathy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Small-fiber neuropathy presents as a painful sensory neuropathy. The initial symptoms are painful dysesthesias in the distal portions of the limbs, most often in the lower extremities. The pain is often described as burning, shock-like, or prickly [<a href="#rid57">57,58</a>] and is associated with allodynia (pain with nonpainful stimuli) and hyperalgesia (exaggerated response to painful stimuli). In the majority of patients, the spread of dysesthesias occurs over months to years to involve more proximal regions, including the trunk and the face [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Affected patients most commonly have a distal and symmetric distribution of burning paresthesia, most likely due to a dying-back axonopathy [<a href="#rid53">53</a>]. However, some patients may have an asymmetric and patchy "non-length-dependent" distribution, not confined to the distal extremities [<a href="#rid47">47</a>]. This may represent a dorsal root ganglionitis affecting unmyelinated or thinly myelinated neurons [<a href="#rid59">59</a>]. In one study, high-resolution magnetic resonance neurography demonstrated abnormalities of the dorsal root ganglia in 5 of 10 SjD patients with proximal neuropathic pain [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">Examination usually demonstrates loss of pinprick and temperature sensation. Functions mediated by large nerve fibers, including muscle strength, light touch and vibratory sensation, proprioception, and deep tendon reflexes, are preserved [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Autonomic symptoms may also occur in this form of neuropathy, including alterations in sweating, micturition, pupillary accommodation, or bowel function.</p><p></p><p class="bulletIndent1">SjD patients with small-fiber sensory neuropathy have a lower prevalence of anti-Ro/SSA antibodies and are more commonly male when compared with those without [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – There are no electrophysiologic abnormalities in patients with small-fiber neuropathy unless there is a concomitant large-fiber neuropathy [<a href="#rid53">53,61</a>].</p><p></p><p class="bulletIndent1">The diagnosis is most often based on a significantly decreased density of epidermal nerve fibers in a skin biopsy from an affected region. The distribution of abnormal nerve fiber density in skin biopsies obtained in proximal and distal sites of the same limb can help differentiate length- versus non-length-dependent neuropathies [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/14144.html" rel="external">"Skin biopsy for the evaluation of peripheral nerve disease"</a>.)</p><p></p><p class="bulletIndent1">Other diagnostic modalities include quantitative sensory testing for thermal sensations, orthostatic blood pressure measurements, laser-evoked potentials, sympathetic skin response, and electrochemical skin conductance, but these are available primarily in specialized centers and are not required in routine clinical practice [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1">A small-fiber neuropathy can have multiple etiologies in addition to or instead of SjD. In a population-based study of Olmsted, Minnesota, the overall prevalence of this neuropathy was 13.3 per 100,000, and SjD accounted for 2 percent of cases. Other causes included diabetes mellitus (15 percent), amyloidosis (2 percent), Fabry disease (1 percent), and post-viral (1 percent) [<a href="#rid63">63</a>]. Seventy percent of the cases were classified as idiopathic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment for small-fiber sensory neuropathy is symptomatic and is similar to that for other causes of small-fiber sensory neuropathy except that in patients with SjD, medications with anticholinergic side effects are avoided [<a href="#rid64">64</a>]. These treatments are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5280.html" rel="external">"Management of diabetic neuropathy", section on 'Pain management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pain relief, we generally initiate therapy with the anticonvulsant calcium channel alpha 2 delta ligands (<a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>). To avoid somnolence and other troublesome side effects, we gradually titrate the doses of these medications upward over three to four months. The serotonin-norepinephrine reuptake inhibitors (eg, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>, <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>) are also effective and particularly useful in those patients with coexisting depression [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tricyclic antidepressants (eg, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a>, <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a>) should generally be avoided, if possible, in SjD patients due to their anticholinergic side effects, but may occasionally be tolerated when introduced at a low dose and titrated slowly [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) has been reported to be effective for severe or treatment-refractory cases in small series and reports [<a href="#rid7">7,65-67</a>]. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> is generally ineffective [<a href="#rid7">7</a>]. Small studies evaluating <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in painful sensory neuropathy have had disappointing results [<a href="#rid55">55</a>]. In our experience, patients with a small-fiber neuropathy whose area of numbness on clinical examination enlarges subacutely over weeks may be more responsive to immunomodulatory therapy compared with patients with a very slowly progressive neuropathy.</p><p></p><p class="headingAnchor" id="H3124098889"><span class="h2">Sensory ataxic neuronopathy</span><span class="headingEndMark"> — </span>Sensory ataxic neuronopathy is a rare yet devastating form of PNS disease, occurring in less than 5 percent of SjD patients [<a href="#rid54">54</a>], although in some series, it makes up a larger proportion of neuropathic syndromes [<a href="#rid7">7</a>]. This distinctive neuropathy is related to a dorsal root ganglionitis [<a href="#rid9">9,10</a>]. In patients with SjD, the initial symptoms often precede the diagnosis of SjD by years [<a href="#rid50">50</a>].</p><p></p><p>Small-fiber sensory neuropathy and sensory ataxic neuronopathy may occur together [<a href="#rid7">7</a>] and have a common pathogenesis (see <a class="local">'Small-fiber neuropathy'</a> above). In an autopsy study of two primary SjD patients, one with painful sensory neuropathy and the other with sensory ataxic neuronopathy, CD8+ lymphocytic infiltration of the dorsal root ganglia and reduction of dorsal root ganglion neurons were observed in both [<a href="#rid59">59</a>]. Thus, both of these clinical syndromes may arise from a dorsal root ganglionitis, with variable involvement of large and small neurons.</p><p>Autonomic neuropathy is also commonly seen in patients with sensory ataxic neuronopathy [<a href="#rid68">68</a>]. (See <a class="local">'Autonomic neuropathy'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The initial symptom of a sensory neuronopathy is asymmetric paresthesia in the digits of the foot or hand that progresses over months to years to include the limbs, trunk, and face [<a href="#rid7">7,50</a>]. The subjective sensory symptoms can remain asymmetric or multifocal.</p><p></p><p class="bulletIndent1">There is prominent loss of kinesthesia and proprioception, leading to gait ataxia, pseudoathetosis of the fingers and toes, and difficulties finding the limbs in space [<a href="#rid9">9</a>]. On examination, Romberg test is positive and generalized areflexia is typically present. There may be a slight reduction in pain and thermal sensation, but strength is preserved [<a href="#rid68">68,69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – Evaluation of patients with this clinical syndrome includes EMG/NCS to characterize the neuropathy and MRI of the spine to exclude polyradiculopathy. On NCS, CMAPs are preserved while SNAPs are absent or have a markedly low amplitude [<a href="#rid7">7</a>]. Both sensory and muscle nerve conduction velocities are typically preserved. Somatosensory evoked potentials can be absent [<a href="#rid7">7</a>]. On MRI of the spine, T2-weighted images may reveal hyperintensity of the dorsal columns, related to sensory ganglionic neuron injury or axonal degeneration [<a href="#rid7">7,69</a>].</p><p></p><p class="bulletIndent1">Patients with sensory neuronopathy should be evaluated for paraneoplastic syndrome and infections that can also cause this syndrome. In contrast to these conditions, in SjD, cerebrospinal fluid (CSF; if obtained) typically has normal to mildly elevated protein levels with normal cell counts [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Subacute sensory neuronopathy'</a>.)</p><p></p><p class="bulletIndent1">Peripheral nerve biopsies are characterized by a marked decrease in the number of large myelinated fibers and a milder decrease in other types of fibers [<a href="#rid7">7</a>]. There may also be epineural and perivascular inflammation and, less commonly, chronic vasculitis of arterioles in the epineural space. Biopsies of the sensory ganglion, when reported, have been notable for a marked CD8+ T-lymphocytic infiltrate with neuronal cell death [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prognosis</strong> – This rare and disabling form of neuropathy is often difficult to treat. Patients with advanced disease may become wheelchair users.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is suggested as a first line of treatment [<a href="#rid70">70</a>]. Early institution of IVIG has been associated with some benefit [<a href="#rid71">71,72</a>]. In a series of five patients, marked improvement with IVIG was seen in four [<a href="#rid71">71</a>]. A second series reported a variable response to IVIG (2 g/kg), with two patients improving, three stabilizing, and four worsening [<a href="#rid65">65</a>]. Other series have reported less successful outcomes with IVIG, with improvement in only 3 of 13 patients in one series and 1 of 6 patients in another series [<a href="#rid7">7,73</a>]. Delayed therapy has been postulated to lead to poor therapeutic response [<a href="#rid54">54</a>] and may account in part for these conflicting reports of response to IVIG.</p><p></p><p class="bulletIndent1">Plasmapheresis is an alternative to <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, but there are less data supporting its use in this condition [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">Glucocorticoids are a widely reported therapeutic modality, often in conjunction with other immunosuppressive agents, but many patients do not respond to this treatment [<a href="#rid7">7,61,73,75</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF) at a dose of 2 grams per day has also been reported to be an effective treatment in one series [<a href="#rid73">73</a>] but not another [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1">Several reports have documented success with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid76">76,77</a>], while others, in the absence of cryoglobulinemia or vasculitis, have been disappointing [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1">Other therapies with some anecdotal reports of efficacy include <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">d-penicillamine</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, and interferon alpha [<a href="#rid9">9,73,78,79</a>].</p><p></p><p class="headingAnchor" id="H2967616054"><span class="h2">Multiple mononeuropathy</span><span class="headingEndMark"> — </span>Multiple mononeuropathy (also called mononeuritis multiplex) occurred in 3 percent of 102 primary SjD patients in one study [<a href="#rid37">37</a>].</p><p>The initial symptoms of multiple mononeuropathy include the acute onset of paresthesia or painful dysesthesia in the distal limbs. Subsequently, motor and sensory symptoms occur episodically and extend to multiple nerve distributions, primarily in the limbs. The sudden onset and mononeuritis multiplex pattern are suggestive of a vasculitic neuropathy and are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">"Clinical manifestations and diagnosis of vasculitic neuropathies", section on 'Multiple mononeuropathy'</a>.)</p><p>This form of neuropathy can be associated with cryoglobulinemia accompanying SjD.</p><p>In patients with multiple mononeuropathy, EMG/NCS is consistent with axonal damage involving multiple individual nerves in an asymmetric fashion. Nerve and muscle biopsy is required to confirm the diagnosis of vasculitic neuropathy unless vasculitis is confirmed by biopsy of other involved organs. Biopsy of affected nerves often shows axonal degeneration and a perivascular inflammatory infiltrate, suggesting an underlying vasculitic cause in many cases [<a href="#rid5">5</a>]. However, lymphocytic neural infiltration without vasculitis has been noted in some patients [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">"Clinical manifestations and diagnosis of vasculitic neuropathies", section on 'Nerve/muscle biopsy'</a>.)</p><p>The treatment of vasculitic multiple mononeuropathy is described separately (see  <a class="medical medical_review" href="/z/d/html/8221.html" rel="external">"Treatment and prognosis of nonsystemic vasculitic neuropathy"</a>). In patients with SjD, both <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> have been reported to be associated with high response rates in small case series [<a href="#rid36">36,50,55</a>].</p><p class="headingAnchor" id="H325101705"><span class="h2">Trigeminal neuropathy</span><span class="headingEndMark"> — </span>The characteristic feature of trigeminal neuropathy is numbness or paresthesia restricted to the trigeminal region. Usually one side of the face is affected; however, bilateral involvement appears to be more common in SjD compared with idiopathic trigeminal neuralgia [<a href="#rid7">7,80,81</a>]. While trigeminal neuralgia in other clinical settings is typified by sharp attacks of facial pain with cutaneous triggers, trigeminal neuropathy in patients with SjD primarily presents as persistent numbness in the face. Another potentially distinguishing feature is that trigeminal nerve dysfunction in SjD is caused by damage to the gasserian ganglion, thus sparing the ophthalmic division and thereby preserving the corneal reflex. One case report describes masseter and temporalis muscle weakness in a patient with SjD and trigeminal nerve involvement [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">"Trigeminal neuralgia", section on 'Clinical features'</a>.)</p><p>The evaluation and differential diagnosis of trigeminal neuralgia is described separately. (See  <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">"Trigeminal neuralgia", section on 'Evaluation and diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">"Trigeminal neuralgia", section on 'Differential diagnosis'</a>.)</p><p><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> and <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> may provide symptom relief of pain [<a href="#rid83">83,84</a>]. Treatment for painful cranial neuropathies can also follow similar strategies to those used for painful peripheral neuropathies, as described for patients with small-fiber neuropathy as well as for patients with idiopathic trigeminal neuralgia, although, as with small-fiber neuropathy, medications with anticholinergic side effects should be avoided in patients with SjD. (See  <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">"Trigeminal neuralgia", section on 'Medical treatment'</a>.)</p><p>Immunosuppressive therapy is not typically prescribed specifically for this syndrome, although in one series, one of three patients treated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> appeared to respond to treatment [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H119733642"><span class="h2">Autonomic neuropathy</span><span class="headingEndMark"> — </span>The prevalence of autonomic neuropathy is difficult to estimate. In studies of peripheral neuropathies in SjD, it is the rarest to occur in pure form [<a href="#rid7">7,47</a>]. However, mild autonomic dysfunction is common in SjD, and is seen in up to half of patients when evidenced by abnormal cardiovascular reflex testing, delayed gastric emptying, urinary bladder dysfunction, and the quantitative sudomotor axon reflex test [<a href="#rid47">47,70,85</a>]. Many of these findings may be from autonomic dysfunction rather than progressive destruction of autonomic nerves.</p><p>This form of autonomic neuropathy may occur in association with a sensory ataxic neuropathy [<a href="#rid9">9</a>] or pure small-fiber sensory neuropathy (the small-fiber nerves mediate autonomic function in addition to perception of pain and temperature). Of note, many clinical factors, including concurrent medications and general deconditioning, influence autonomic testing results, which should be interpreted in the overall context of patient's clinical history.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Clinically overt autonomic neuropathies are manifested by orthostatic hypotension, fixed tachycardia, hypohidrosis or anhidrosis of the trunk and limbs, abdominal pain, constipation, diarrhea, and Adie's pupil (a dilated pupil that is poorly reactive to light but does react slowly to accommodation); these are similar to signs seen in diabetic autonomic neuropathy. These signs are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5285.html" rel="external">"Diabetic autonomic neuropathy"</a>.)</p><p></p><p class="bulletIndent1">Autonomic dysfunction may also contribute to the decreased lacrimation and salivation of the sicca complex [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/z/d/html/5620.html" rel="external">"Pathogenesis of Sjögren’s disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The management of autonomic neuropathy is primarily symptomatic. The treatment options for orthostatic hypotension due to autonomic neuropathy may include <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> acetate, sympathomimetic agents such as <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">midodrine</a>, or beta blockers. (See  <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">"Treatment of orthostatic and postprandial hypotension"</a>.)</p><p></p><p class="bulletIndent1">Visceral autonomic motor dysfunctions such as impaired gastric motility or bladder involvement have clinical similarities to those found in diabetic patients, and similar treatments have been proposed and are described separately. (See  <a class="medical medical_review" href="/z/d/html/2643.html" rel="external">"Diabetic autonomic neuropathy of the gastrointestinal tract"</a> and  <a class="medical medical_review" href="/z/d/html/5285.html" rel="external">"Diabetic autonomic neuropathy", section on 'Genitourinary autonomic neuropathy'</a>.)</p><p></p><p class="bulletIndent1">Patients with severe forms of autonomic neuropathy have been treated with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> [<a href="#rid65">65</a>] or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid55">55,65,87,88</a>]. The response is often mixed, and complete resolution is unusual.</p><p></p><p class="headingAnchor" id="H694268544"><span class="h2">Multiple cranial neuropathies</span><span class="headingEndMark"> — </span>Some patients present with multiple nerve syndromes: as many as six cranial nerves may be involved in an individual patient [<a href="#rid7">7</a>]. The cranial nerves most commonly affected are VII (Bell palsy); VIII (resulting in neural deafness and vestibular dysfunction); and III, IV, or VI (resulting in diplopia). The acute onset of a cranial neuropathy should prompt concern for a vasculitic neuropathy, particularly when it is associated with multiple mononeuropathies in the extremities [<a href="#rid54">54</a>].</p><p>Hearing may also be affected in a significant proportion of patients, although many cases are subclinical [<a href="#rid89">89</a>]. In a study of 30 SjD patients, 14 (46 percent) had sensorineural hearing loss on audiometric testing, compared with only 2.5 percent of the controls. Five of the 14 SjD patients had clinically apparent hearing loss [<a href="#rid90">90</a>].</p><p>While patients with SjD may develop impaired smell and taste, these deficits are believed to result from the effects of salivary hypofunction rather than a cranial nerve syndrome [<a href="#rid70">70</a>].</p><p>Patients with this presentation should undergo contrast-enhanced MRI and CSF evaluation.<em> </em>The differential diagnosis depends in part on the pattern of nerves involved, but includes other structural disease of the brain stem as well as meningitic processes such as chronic infections and cancer.</p><p>Multiple cranial neuropathies in SjD may respond to glucocorticoids [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1520736835"><span class="h2">Demyelinating radiculoneuropathy</span><span class="headingEndMark"> — </span>This disorder has been described in a few patients with SjD and is characterized by sensory and motor dysfunction restricted to the spinal roots or proximal spinal nerve trunk [<a href="#rid7">7,37,91,92</a>]. The CSF protein concentration is usually elevated, but pleocytosis is absent. EMG/NCS demonstrate prolonged latencies consistent with a demyelinating neuropathy. These small case series have also noted gadolinium enhancement in the dorsal spinal roots on spinal MRI as well as evidence of demyelination on sural nerve biopsy in a few patients. These clinical features are similar to those of chronic inflammatory demyelinating polyneuropathy (CIDP), and it is unclear whether these are concurrent autoimmune disorders or whether this syndrome is an SjD disease manifestation. (See  <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis"</a>.)</p><p><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> has been reported to be effective for treatment of this syndrome in patients with SjD, and IVIG regimens are used for the treatment of patients with CIDP without SjD [<a href="#rid7">7</a>]. The management of CIDP, including the use and dosing of IVIG for this syndrome, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5265.html" rel="external">"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H4224995599"><span class="h1">CENTRAL NERVOUS SYSTEM DISORDERS</span><span class="headingEndMark"> — </span>In many patients, the neurologic symptoms affecting the central nervous system (CNS) precede the onset of other signs and symptoms of SjD [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H1971235563"><span class="h2">Focal or multifocal demyelination/inflammation</span><span class="headingEndMark"> — </span>SjD has been associated with demyelinating disorders in case reports and series. Any part of the brain or spinal cord can be affected in patients with SjD. The pattern is generally one of multifocal recurrent episodes, often separated by long disease-free intervals, resulting in an insidious progressive neurologic deficit [<a href="#rid50">50</a>]. In most patients, these demyelinating disorders fulfill criteria for multiple sclerosis or neuromyelitis optica spectrum disorder (NMOSD) and can be considered associated with SjD rather than a specific SjD manifestation [<a href="#rid30">30</a>].</p><p>The range of CNS findings has been defined in several series of primary SjD patients [<a href="#rid50">50,93,94</a>] and is described below. The most common forms of CNS involvement are focal/multifocal, diffuse, and spinal cord.</p><p class="headingAnchor" id="H3018027051"><span class="h3">Clinical syndromes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic MRI lesions</strong> – In SjD, there is an increased prevalence of nonspecific T2-weighted white matter hyperintensities on MRI of the brain, usually in the absence of focal neurologic signs or symptoms [<a href="#rid41">41,43</a>]. In the absence of localizing findings, these white matter lesions occur at similar rates between SjD patients and age- and sex-matched controls [<a href="#rid42">42</a>] and correlate more with age and cardiovascular risk factors, such as hypertension and hyperlipidemia, than the underlying disease [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optic neuritis</strong> – Optic neuritis presents with monocular vision loss and eye pain and may be the presenting symptom or a later complication in patients with SjD-associated demyelinating syndromes [<a href="#rid96">96-99</a>]. The presentation, differential diagnosis, and evaluation of patients presenting with optic neuritis are described separately. (See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transverse myelitis</strong> – Spinal cord involvement in SjD can take the form of an acute transverse myelopathy or a longitudinally extensive (greater than three vertebral segments) myelopathy. The latter form of myelopathy is usually located in the cervical spinal cord, in contrast to idiopathic transverse myelitis, which is most often located in the thoracic spinal cord [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NMOSD</strong> – In patients with SjD, transverse myelitis is often associated with antibodies to aquaporin-4 (AQP4) and falls within the spectrum of neuromyelitis optica spectrum disorders (NMOSD) [<a href="#rid12">12,101</a>]. In a review of published cases of longitudinally extensive myelitis associated with SjD, approximately 89 percent (17 of 19 patients) had positive AQP4 antibody [<a href="#rid101">101</a>]. Patients with SjD and AQP4 antibody behave like patients with conventional NMOSD in terms of relapse frequency and imaging findings in the brain and spine [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other causes</strong> – Myelitis associated with a longitudinal T2-hyperintense lesion in the cervical spinal cord was reported in four SjD patients, each without AQ4 or myelin oligodendrocyte (MOG) antibodies [<a href="#rid102">102</a>]. Cerebrospinal fluid (CSF) neurofilament light chain levels, a measure of neuroaxonal damage, were elevated in these patients compared with controls, and two patients demonstrated intrathecal synthesis of anti-SSA/Ro antibodies.</p><p></p><p class="bulletIndent2">Progressive spastic paraparesis in a patient with SjD was associated with presence of anti-Ma2/Ta antibody without underlying cancer [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1">The clinical syndrome and differential diagnosis of transverse myelitis are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14088.html" rel="external">"Transverse myelitis: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NMOSD</strong> – One case series describes 12 SjD patients (all with positive anti-Ro/SSA and anti-La/SSB antibodies) who had relapsing and remitting CNS symptoms and brain involvement, characteristic of NMOSD [<a href="#rid12">12</a>]. These included lesions adjacent to the third and fourth ventricles (10 patients), longitudinal lesions from the internal capsule to the brainstem (eight patients), large and confluent cerebral and cerebellar lesions of &gt;3 cm in length (eight patients), and cavity formation (seven patients). The AQP4 antibody was found in six of eight patients in whom it was tested.</p><p></p><p class="bulletIndent1">Several findings have supported the concept that NMOSD is not a direct manifestation of SjD, but rather an overlap of two distinct autoimmune diseases [<a href="#rid104">104-106</a>]. These include the high specificity of AQP4 antibodies for NMO, similarities in antibody profile between SjD patients with and without NMOSD, and similarities in CNS lesions between NMOSD patients with and without SjD.</p><p></p><p class="bulletIndent1">NMOSD is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple sclerosis-like presentations</strong> – Since multiple sclerosis is also a common disorder affecting patients with the same demographics as SjD, comorbid multiple sclerosis has to be considered in SjD patients developing demyelinating CNS lesions. Whether there is a linkage between the two diseases has been controversial without large series to substantiate claims. In patients with primary progressive multiple sclerosis, higher than background prevalence of SjD has been found [<a href="#rid107">107</a>]. Others have suggested that patients with SjD-associated myelopathy may instead be misdiagnosed with multiple sclerosis [<a href="#rid108">108</a>]. Advances in MRI brain sequences have allowed for detection of central veins through brain lesions. Multiple sclerosis lesions generally have a significantly higher frequency of veins traversing centrally through the lesions ("central vein sign") when compared with SjD; it is uncertain whether this is a reliable tool to distinguish SjD from multiple sclerosis [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other focal presentations</strong> – Some patients with SjD present with focal brain lesions that may result in motor or sensory deficits, seizures, or cerebellar syndromes.</p><p></p><p class="bulletIndent1">Focal demyelinating symptoms and their differential diagnosis are described separately. (See  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Clinically isolated syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">"Manifestations of multiple sclerosis in adults"</a>.)</p><p></p><p class="bulletIndent1">Chorea has been described as a presenting symptom of SjD [<a href="#rid110">110,111</a>].</p><p></p><p class="headingAnchor" id="H3866609298"><span class="h3">Evaluation</span><span class="headingEndMark"> — </span>Management of demyelinating disease requires careful consideration of the likely etiology. White matter lesions on MRI may be a reflection of comorbid conditions, including aging, hypertension, and hyperlipidemia, rather than an autoimmune lesion, given that the majority of SjD patients are middle aged and older [<a href="#rid95">95</a>].</p><p>Alternative diagnoses such as multiple sclerosis or NMOSD have to be excluded before attributing symptoms and findings to SjD. We suggest that patients with these syndromes be evaluated according to their syndrome presentation, regardless of whether they have a diagnosis of SjD or not. Typically this evaluation includes neuroimaging, CSF evaluation, and in some patients, serologic testing as well. These evaluations are described in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14088.html" rel="external">"Transverse myelitis: Etiology, clinical features, and diagnosis", section on 'Initial evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2523206436"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Acute attacks of demyelination are typically treated with intravenous pulse <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, 1 gram daily for three to five days [<a href="#rid112">112,113</a>]. Plasmapheresis is utilized for patients whose neurologic disease does not respond to glucocorticoids [<a href="#rid114">114</a>] (see  <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">"Treatment of acute exacerbations of multiple sclerosis in adults"</a>). In patients with severe attacks of NMOSD, there are limited data to suggest improved outcomes if plasmapheresis is started early as adjunctive therapy with glucocorticoids. (See  <a class="medical medical_review" href="/z/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis", section on 'Acute attacks'</a>.)</p><p>The distinction of NMOSD from SjD-related myelopathy may not be feasible, and presumptive therapy for NMOSD is thus recommended, particularly in the setting of positive AQP4 antibodies. Remission may be maintained with <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) [<a href="#rid112">112,113</a>]. If AQP4 antibodies are negative, long-term immunosuppression may rely on mycophenolate, azathioprine, or rituximab in lieu of eculizumab, similar to treatment of other patients with antibody-negative NMOSD. (See  <a class="medical medical_review" href="/z/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis"</a>.)</p><p>Similarly, for other demyelinating syndromes, the indications for chronic immunomodulatory treatment mirror those used in patients without SjD. (See  <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">"Optic neuritis: Prognosis and treatment", section on 'Disease-modifying therapy'</a> and  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/142457.html" rel="external">"Transverse myelitis: Treatment and prognosis", section on 'Recurrent idiopathic TM'</a>.)</p><p class="headingAnchor" id="H1134758534"><span class="h2">Cognitive dysfunction</span><span class="headingEndMark"> — </span>Changes in cognitive function with poor memory and concentration are commonly reported by SjD patients, often using the term "brain fog." The severity of these symptoms can range from subtle cognitive impairments to frank dementia [<a href="#rid94">94,115-117</a>].</p><p>In most cases, the symptoms are relatively mild; the specificity of this mild encephalopathy to SjD as opposed to any disabling chronic medical illness needs to be evaluated further [<a href="#rid117">117</a>]. One series of 431 consecutive primary SjD patients describes six with a recurrent subacute encephalopathy, characterized by memory loss, cognitive dysfunction, visual disturbances, and reduced performance in concentration and attention [<a href="#rid94">94</a>]. Each had small punctate hyperintense white matter lesions on MRI, but no focal neurologic signs. In other reports, abnormalities on objective neuropsychiatric testing have included reduced psychomotor processing, verbal reasoning, memory, attention, and concentration ability [<a href="#rid23">23,27,118-120</a>], but some studies have failed to show consistent differences between primary SjD patients and controls [<a href="#rid23">23</a>]. Fatigue and depression may have a role in the genesis of this cognitive dysfunction [<a href="#rid120">120</a>].</p><p>Other case series also report that MRI studies are normal or have minor nonspecific abnormalities [<a href="#rid27">27</a>]. Regional areas of cortical hypoperfusion on single-photon emission computed tomography (SPECT) were reported in one series of patients with SjD-associated cognitive dysfunction [<a href="#rid27">27</a>].</p><p>SjD should not be assumed to be the cause of cognitive dysfunction [<a href="#rid117">117</a>]. Patients should be evaluated for thyroid dysfunction, vitamin B12 deficiency, sleep disturbances, affective disorders, and medication side effects. Neuroimaging and CSF analysis should be reserved for patients with severe symptoms and/or objective evidence of impairment in one or more cognitive domains, as assessed in the clinical interview and with the aid of a screening tool, such as the Folstein Mini-Mental State Examination. The evaluation of patients with cognitive impairment is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Evaluation'</a>.)</p><p>For indolent manifestations such as psychiatric changes or mental fog, monitoring with supportive therapy is appropriate. (See  <a class="medical medical_review" href="/z/d/html/5091.html" rel="external">"Mild cognitive impairment: Prognosis and treatment", section on 'Treatment'</a>.)</p><p>One case report documented improvement of SjD-related dementia with high-dose glucocorticoid therapy [<a href="#rid115">115</a>]. This patient had normal brain MRI, CSF, and angiography but had perivascular inflammation on brain biopsy. Immunosuppression in SjD patients with dementia should only be pursued after alternative and more common causes of dementia have been excluded and/or an inflammatory process is documented. Neuropsychiatric testing should be performed before and after a glucocorticoid trial to ensure objective improvement has occurred prior to initiation of glucocorticoid-sparing therapy.</p><p class="headingAnchor" id="H4055475828"><span class="h2">Meningoencephalitis</span><span class="headingEndMark"> — </span>Meningoencephalitis has been reported in a few cases. The largest case series described five patients, four of whom had recurrent episodes [<a href="#rid121">121</a>]. All presented with fever, myalgias, meningismus, and delirium. CSF had leukocytosis (ranging from 33 to 900 cells/microL with variable neutrophilic or lymphocytic predominance), mildly elevated protein, and an elevated CSF immunoglobulin G (IgG) index. Vasculitis involving veins, arterioles, and small arteries was documented in skin or muscle biopsies of three of the five patients, but cerebral angiography failed to show changes indicative of medium-sized vessel vasculitis.</p><p>A separate series of recurrent meningoencephalitis cases described intracranial angiographic changes suggestive of vasculopathy and biopsies consistent with vasculitis [<a href="#rid26">26</a>]. Subacute aseptic meningitis with diffuse leptomeningeal enhancement has also been reported [<a href="#rid122">122,123</a>].</p><p>Patients with SjD who present with meningoencephalitis require thorough CSF evaluation to exclude infectious causes. (See  <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">"Aseptic meningitis in adults"</a>.)</p><p>Spontaneous recovery without treatment has been reported. Treatment with glucocorticoids alone or in conjunction with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> has been reported as successful in case series and isolated case reports [<a href="#rid121">121,124-126</a>]. One reported case improved markedly following plasmapheresis [<a href="#rid127">127</a>].</p><p class="headingAnchor" id="H438801865"><span class="h2">Autoimmune encephalitis</span><span class="headingEndMark"> — </span>Encephalitis associated with antibodies to neuronal proteins and synaptic receptors, including anti-Ma2 and anti-N-methyl-D-aspartate receptor, has been reported rarely in SjD [<a href="#rid128">128,129</a>]. Autoimmune encephalitis is described separately. (See  <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H2356070308"><span class="h2">Other associations</span><span class="headingEndMark"> — </span>Some studies find that headache is more prevalent in patients with SjD than controls [<a href="#rid24">24,130-132</a>]. However, studies have differed as to the strength of this association as well as the most common headache type (eg, migraine, tension headache). At present, we evaluate and treat patients according to their headache type. (See  <a class="medical medical_review" href="/z/d/html/3349.html" rel="external">"Evaluation of headache in adults"</a>.)</p><p>Psychiatric disorders (in particular, affective disorders [depression and anxiety]) are common in SjD patients and may contribute to neurologic symptoms, particularly cognitive impairment. (See  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Psychiatric disorders'</a>.)</p><p>Rare cases of motor neuron disease have been described in patients with SjD [<a href="#rid133">133-135</a>].</p><p class="headingAnchor" id="H4132954620"><span class="h1">SUPPORT FOR TREATMENT APPROACHES</span><span class="headingEndMark"> — </span>The treatment approach to neurologic manifestations of SjD is based upon clinical practice guidelines, case series, limited clinical trial data for a few agents, our clinical experience, expert opinion, and indirect evidence from the use of these agents in other autoimmune rheumatic disorders. (See  <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Therapeutic rationale and evidence overview'</a> and  <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Efficacy of specific therapeutic agents'</a>.)</p><p class="headingAnchor" id="H1579942797"><span class="h1">EVALUATION FOR SJÖGREN'S DISEASE IN PATIENTS WITH NEUROLOGIC DISEASE</span><span class="headingEndMark"> — </span>Neurologic symptoms precede a diagnosis of SjD in most cases, up to 93 percent in one series [<a href="#rid7">7,34,35</a>]. However, many of these patients will have symptoms of dry eyes, dry mouth, or other features of SjD, which should raise suspicion for this disorder. (See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease", section on 'Symptoms of dry eyes and mouth'</a>.)</p><p>For most of these neurologic syndromes, SjD is not among the first tier of diagnoses being considered, but SjD should be suspected in patients with persistent symptoms of dry eyes and/or mouth, parotid gland enlargement, or an unexplained increase in dental caries and in those in whom a cause is not identified after initial testing.</p><p>The evaluation can include serologic testing for anti-Ro/SSA and anti-La/SSB antibodies, rheumatoid factor, and antinuclear antibodies; testing for hyperglobulinemia; and an ophthalmologic evaluation. The latter should be performed by an expert in eye disease and typically includes Schirmer testing, a slit-lamp examination, and ocular surface staining. Some patients may require formal testing of salivary function, a labial salivary gland biopsy, and/or imaging studies to confirm a diagnosis of SjD. Among patients who present with neuropathy, the Schirmer test for dry eye and salivary gland biopsy appear to have higher sensitivity than serologic testing [<a href="#rid7">7</a>]. The evaluation and diagnosis of SjD are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a>.)</p><p class="headingAnchor" id="H1764718916"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117117.html" rel="external">"Society guideline links: Sjögren's disease"</a>.)</p><p class="headingAnchor" id="H3949486677"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/85725.html" rel="external">"Patient education: Sjögren's disease (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/580.html" rel="external">"Patient education: Sjögren's disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2663178810"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and evaluation for SjD</strong> – Sjögren's disease (SjD) can cause peripheral nervous system (PNS) and brain abnormalities. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Peripheral neuropathy affects approximately 10 percent of patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Estimates of central nervous system (CNS) involvement vary quite widely, and the nature and frequency of CNS manifestations remain controversial.</p><p></p><p class="bulletIndent1">Neurologic symptoms frequently precede the diagnosis of SjD. The presence of sicca symptoms may point to a diagnosis of SjD and should prompt a formal evaluation for this disease. (See <a class="local">'Evaluation for Sjögren's disease in patients with neurologic disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral nervous system disease</strong> – SjD is associated with a variety of PNS abnormalities. Overlap may occur among the different forms of peripheral neuropathy. The relative frequency of these syndromes varies widely among case series. (See <a class="local">'Peripheral nervous system disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The evaluation of the neuropathy is tailored to the clinical syndrome, but often includes electrophysiologic studies: electromyography (EMG) and nerve conduction studies (NCS) that help to confirm the syndrome. Skin and/or nerve biopsies and other evaluations are recommended in specific syndromes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recommended treatment approaches are based upon anecdotal evidence of efficacy and/or studies in patients with similar syndromes occurring in diseases other than SjD.</p><p></p><p class="bulletIndent2">Immunotherapy for peripheral nerve disease is typically limited to patients with disabling symptoms, symptoms not responsive to symptomatic therapies, and/or those with a documented vasculitic component.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNS demyelination</strong> – Demyelinating disorders are sometimes seen in patients with SjD. Any part of the brain or spinal cord can be affected; in particular, a number of patients with neuromyelitis optica spectrum disorders (NMOSD) have been described. It is not clear whether SjD is the cause of the demyelination or if this represents an autoimmune diseases association. (See <a class="local">'Focal or multifocal demyelination/inflammation'</a> above.)</p><p></p><p class="bulletIndent1">A diagnostic evaluation should be undertaken that is similar to that for patients who have one of these syndromes without a history of SjD. Similarly, we suggest treatment approaches similar to those for patients with these syndromes outside the context of SjD. These are described in individual topic reviews. (See <a class="local">'Focal or multifocal demyelination/inflammation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive impairment</strong> – While commonly reported by SjD patients, it is unclear to what extent complaints of poor memory and concentration are specific to SjD as opposed to other disabling chronic medical illnesses. Patients with cognitive impairment should be fully evaluated for other causes. (See <a class="local">'Cognitive dysfunction'</a> above and  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meningoencephalitis</strong> – Meningoencephalitis is a rare complication of SjD and generally has a benign prognosis, with spontaneous recovery or resolution with glucocorticoids or other short-term immunotherapy. (See <a class="local">'Meningoencephalitis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">McCoy SS, Baer AN. Neurological Complications of Sjögren's Syndrome: Diagnosis and Management. Curr Treatm Opt Rheumatol 2017; 3:275.</a></li><li><a class="nounderline abstract_t">Margaretten M. Neurologic Manifestations of Primary Sjögren Syndrome. Rheum Dis Clin North Am 2017; 43:519.</a></li><li><a class="nounderline abstract_t">Bhattacharyya S, Helfgott SM. Neurologic complications of systemic lupus erythematosus, sjögren syndrome, and rheumatoid arthritis. Semin Neurol 2014; 34:425.</a></li><li><a class="nounderline abstract_t">Alunno A, Carubbi F, Bartoloni E, et al. The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. Clin Exp Rheumatol 2019; 37 Suppl 118:192.</a></li><li><a class="nounderline abstract_t">Mellgren SI, Conn DL, Stevens JC, Dyck PJ. Peripheral neuropathy in primary Sjögren's syndrome. Neurology 1989; 39:390.</a></li><li><a class="nounderline abstract_t">Alexander EL. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum Dis Clin North Am 1993; 19:869.</a></li><li><a class="nounderline abstract_t">Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain 2005; 128:2518.</a></li><li><a class="nounderline abstract_t">Bakchine S, Duyckaerts C, Hassine L, et al. [Central and peripheral neurologic lesions in primary Gougerot-Sjögren syndrome. Clinicopathological study of a case]. Rev Neurol (Paris) 1991; 147:368.</a></li><li><a class="nounderline abstract_t">Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome. Ann Neurol 1990; 27:304.</a></li><li><a class="nounderline abstract_t">Malinow K, Yannakakis GD, Glusman SM, et al. Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndrome. Ann Neurol 1986; 20:535.</a></li><li><a class="nounderline abstract_t">Feldman L, Dhamne M, Li Y. Neurologic manifestations associated with cryoglobulinemia: A single center experience. J Neurol Sci 2019; 398:121.</a></li><li><a class="nounderline abstract_t">Min JH, Kim HJ, Kim BJ, et al. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler 2009; 15:1069.</a></li><li><a class="nounderline abstract_t">Qiao L, Wang Q, Fei Y, et al. The Clinical Characteristics of Primary Sjogren's Syndrome With Neuromyelitis Optica Spectrum Disorder in China: A STROBE-Compliant Article. Medicine (Baltimore) 2015; 94:e1145.</a></li><li><a class="nounderline abstract_t">Murata Y, Maeda K, Kawai H, et al. Antiganglion neuron antibodies correlate with neuropathy in Sjögren's syndrome. Neuroreport 2005; 16:677.</a></li><li><a class="nounderline abstract_t">Eystathioy T, Chan EK, Takeuchi K, et al. Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. J Mol Med (Berl) 2003; 81:811.</a></li><li><a class="nounderline abstract_t">Guo L, Ren H, Fan S, et al. Autoantibody against the Rab6A/Rab6B in primary autoimmune cerebellar ataxia associated with Sjogren's syndrome: A case report. J Neuroimmunol 2021; 359:577667.</a></li><li><a class="nounderline abstract_t">Mukaino A, Nakane S, Higuchi O, et al. Insights from the ganglionic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome. Mod Rheumatol 2016; 26:708.</a></li><li><a class="nounderline abstract_t">Park K, Haberberger RV, Gordon TP, Jackson MW. Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2011; 63:1426.</a></li><li><a class="nounderline abstract_t">Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2000; 43:1647.</a></li><li><a class="nounderline abstract_t">Sène D, Jallouli M, Lefaucheur JP, et al. Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) 2011; 90:133.</a></li><li><a class="nounderline abstract_t">Fan G, Dai F, Chen S, et al. Neurological Involvement in Patients With Primary Sjögren's Syndrome. J Clin Rheumatol 2021; 27:50.</a></li><li><a class="nounderline abstract_t">Indart S, Hugon J, Guillausseau PJ, et al. Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review. Medicine (Baltimore) 2017; 96:e6384.</a></li><li><a class="nounderline abstract_t">Segal BM, Pogatchnik B, Holker E, et al. Primary Sjogren's syndrome: cognitive symptoms, mood, and cognitive performance. Acta Neurol Scand 2012; 125:272.</a></li><li><a class="nounderline abstract_t">Morreale M, Marchione P, Giacomini P, et al. Neurological involvement in primary Sjögren syndrome: a focus on central nervous system. PLoS One 2014; 9:e84605.</a></li><li><a class="nounderline abstract_t">de la Monte SM, Hutchins GM, Gupta PK. Polymorphous meningitis with atypical mononuclear cells in Sjögren's syndrome. Ann Neurol 1983; 14:455.</a></li><li><a class="nounderline abstract_t">Alexander EL, Ranzenbach MR, Kumar AJ, et al. Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994; 44:899.</a></li><li><a class="nounderline abstract_t">Le Guern V, Belin C, Henegar C, et al. Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjogren syndrome: a case-control study. Ann Rheum Dis 2010; 69:132.</a></li><li><a class="nounderline abstract_t">Lauvsnes MB, Maroni SS, Appenzeller S, et al. Memory dysfunction in primary Sjögren's syndrome is associated with anti-NR2 antibodies. Arthritis Rheum 2013; 65:3209.</a></li><li><a class="nounderline abstract_t">Bårdsen K, Nilsen MM, Kvaløy JT, et al. Heat shock proteins and chronic fatigue in primary Sjögren's syndrome. Innate Immun 2016; 22:162.</a></li><li><a class="nounderline abstract_t">Mekinian A, Tennenbaum J, Lahuna C, et al. Primary Sjögren's syndrome: central and peripheral nervous system involvements. Clin Exp Rheumatol 2020; 38 Suppl 126:103.</a></li><li><a class="nounderline abstract_t">Segal B, Thomas W, Rogers T, et al. Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome. Arthritis Rheum 2008; 59:1780.</a></li><li><a class="nounderline abstract_t">Mæland E, Miyamoto ST, Hammenfors D, et al. Understanding Fatigue in Sjögren's Syndrome: Outcome Measures, Biomarkers and Possible Interventions. Front Immunol 2021; 12:703079.</a></li><li><a class="nounderline abstract_t">Carvajal Alegria G, Guellec D, Mariette X, et al. Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. RMD Open 2016; 2:e000179.</a></li><li><a class="nounderline abstract_t">Jamilloux Y, Magy L, Hurtevent JF, et al. Immunological profiles determine neurological involvement in Sjögren's syndrome. Eur J Intern Med 2014; 25:177.</a></li><li><a class="nounderline abstract_t">Lafitte C, Amoura Z, Cacoub P, et al. Neurological complications of primary Sjögren's syndrome. J Neurol 2001; 248:577.</a></li><li><a class="nounderline abstract_t">Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry 2011; 82:798.</a></li><li><a class="nounderline abstract_t">Brito-Zerón P, Akasbi M, Bosch X, et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2013; 31:103.</a></li><li><a class="nounderline abstract_t">Moutsopoulos HM, Sarmas JH, Talal N. Is central nervous system involvement a systemic manifestation of primary Sjögren's syndrome? Rheum Dis Clin North Am 1993; 19:909.</a></li><li><a class="nounderline abstract_t">Binder A, Snaith ML, Isenberg D. Sjögren's syndrome: a study of its neurological complications. Br J Rheumatol 1988; 27:275.</a></li><li><a class="nounderline abstract_t">Hietaharju A, Yli-Kerttula U, Häkkinen V, Frey H. Nervous system manifestations in Sjögren's syndrome. Acta Neurol Scand 1990; 81:144.</a></li><li><a class="nounderline abstract_t">Morgen K, McFarland HF, Pillemer SR. Central nervous system disease in primary Sjogrens syndrome: the role of magnetic resonance imaging. Semin Arthritis Rheum 2004; 34:623.</a></li><li><a class="nounderline abstract_t">Harboe E, Beyer MK, Greve OJ, et al. Cerebral white matter hyperintensities are not increased in patients with primary Sjögren's syndrome. Eur J Neurol 2009; 16:576.</a></li><li><a class="nounderline abstract_t">Coates T, Slavotinek JP, Rischmueller M, et al. Cerebral white matter lesions in primary Sjögren's syndrome: a controlled study. J Rheumatol 1999; 26:1301.</a></li><li><a class="nounderline abstract_t">Dyck PJ. The clinical heterogeneity of immune sensory and autonomic neuropathies with (or without) sicca. Brain 2005; 128:2480.</a></li><li><a class="nounderline abstract_t">England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199.</a></li><li><a class="nounderline abstract_t">Gøransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary sjogren syndrome: a population-based study. Arch Neurol 2006; 63:1612.</a></li><li><a class="nounderline abstract_t">Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012; 39:27.</a></li><li><a class="nounderline abstract_t">Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve 2004; 30:255.</a></li><li><a class="nounderline abstract_t">Krarup C. Nerve conduction studies in selected peripheral nerve disorders. Curr Opin Neurol 2002; 15:579.</a></li><li><a class="nounderline abstract_t">Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83:280.</a></li><li><a class="nounderline abstract_t">Grant IA, Hunder GG, Homburger HA, Dyck PJ. Peripheral neuropathy associated with sicca complex. Neurology 1997; 48:855.</a></li><li><a class="nounderline abstract_t">Terrier B, Lacroix C, Guillevin L, et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy. Arthritis Rheum 2007; 57:1520.</a></li><li><a class="nounderline abstract_t">Chai J, Herrmann DN, Stanton M, et al. Painful small-fiber neuropathy in Sjogren syndrome. Neurology 2005; 65:925.</a></li><li><a class="nounderline abstract_t">Birnbaum J. Peripheral nervous system manifestations of Sjögren syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies. Neurologist 2010; 16:287.</a></li><li><a class="nounderline abstract_t">Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012; 71:84.</a></li><li><a class="nounderline abstract_t">Kampylafka EI, Alexopoulos H, Dalakas MC, Tzioufas AG. Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. Neurotherapeutics 2016; 13:163.</a></li><li><a class="nounderline abstract_t">Hoeijmakers JG, Faber CG, Lauria G, et al. Small-fibre neuropathies--advances in diagnosis, pathophysiology and management. Nat Rev Neurol 2012; 8:369.</a></li><li><a class="nounderline abstract_t">Birnbaum J, Lalji A, Saed A, Baer AN. Biopsy-Proven Small-Fiber Neuropathy in Primary Sjögren's Syndrome: Neuropathic Pain Characteristics, Autoantibody Findings, and Histopathologic Features. Arthritis Care Res (Hoboken) 2019; 71:936.</a></li><li><a class="nounderline abstract_t">Kawagashira Y, Koike H, Fujioka Y, et al. Differential, size-dependent sensory neuron involvement in the painful and ataxic forms of primary Sjögren's syndrome-associated neuropathy. J Neurol Sci 2012; 319:139.</a></li><li><a class="nounderline abstract_t">Birnbaum J, Duncan T, Owoyemi K, et al. Use of a novel high-resolution magnetic resonance neurography protocol to detect abnormal dorsal root Ganglia in Sjögren patients with neuropathic pain: case series of 10 patients and review of the literature. Medicine (Baltimore) 2014; 93:121.</a></li><li><a class="nounderline abstract_t">Font J, Ramos-Casals M, de la Red G, et al. Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature. J Rheumatol 2003; 30:1552.</a></li><li><a class="nounderline abstract_t">Lefaucheur JP, Wahab A, Planté-Bordeneuve V, et al. Diagnosis of small fiber neuropathy: A comparative study of five neurophysiological tests. Neurophysiol Clin 2015; 45:445.</a></li><li><a class="nounderline abstract_t">Johnson SA, Shouman K, Shelly S, et al. Small Fiber Neuropathy Incidence, Prevalence, Longitudinal Impairments, and Disability. Neurology 2021; 97:e2236.</a></li><li><a class="nounderline abstract_t">Khan S, Zhou L. Characterization of non-length-dependent small-fiber sensory neuropathy. Muscle Nerve 2012; 45:86.</a></li><li><a class="nounderline abstract_t">Rist S, Sellam J, Hachulla E, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken) 2011; 63:1339.</a></li><li><a class="nounderline abstract_t">Wakasugi D, Kato T, Gono T, et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren's syndrome. Mod Rheumatol 2009; 19:437.</a></li><li><a class="nounderline abstract_t">Morozumi S, Kawagashira Y, Iijima M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. J Neurol Sci 2009; 279:57.</a></li><li><a class="nounderline abstract_t">Sheikh SI, Amato AA. The dorsal root ganglion under attack: the acquired sensory ganglionopathies. Pract Neurol 2010; 10:326.</a></li><li><a class="nounderline abstract_t">Mori K, Koike H, Misu K, et al. Spinal cord magnetic resonance imaging demonstrates sensory neuronal involvement and clinical severity in neuronopathy associated with Sjögren's syndrome. J Neurol Neurosurg Psychiatry 2001; 71:488.</a></li><li><a class="nounderline abstract_t">Berkowitz AL, Samuels MA. The neurology of Sjogren's syndrome and the rheumatology of peripheral neuropathy and myelitis. Pract Neurol 2014; 14:14.</a></li><li><a class="nounderline abstract_t">Takahashi Y, Takata T, Hoshino M, et al. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin. Neurology 2003; 60:503.</a></li><li><a class="nounderline abstract_t">Danieli MG, Pettinari L, Morariu R, et al. Intravenous Immunoglobulin and Mycophenolate Mofetil for Long-Standing Sensory Neuronopathy in Sjögren's Syndrome. Case Reports Immunol 2012; 2012:186320.</a></li><li><a class="nounderline abstract_t">Pereira PR, Viala K, Maisonobe T, et al. Sjögren Sensory Neuronopathy (Sjögren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases. Medicine (Baltimore) 2016; 95:e3632.</a></li><li><a class="nounderline abstract_t">Chen WH, Yeh JH, Chiu HC. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjögren's syndrome. Eur Neurol 2001; 45:270.</a></li><li><a class="nounderline abstract_t">Font J, Valls J, Cervera R, et al. Pure sensory neuropathy in patients with primary Sjögren's syndrome: clinical, immunological, and electromyographic findings. Ann Rheum Dis 1990; 49:775.</a></li><li><a class="nounderline abstract_t">Alix JJ, Hadjivassiliou M, Ali R, et al. Sensory ganglionopathy with livedoid vasculopathy controlled by immunotherapy. Muscle Nerve 2015; 51:296.</a></li><li><a class="nounderline abstract_t">Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35:66.</a></li><li><a class="nounderline abstract_t">Benezra R, de Candia P, Li H, et al. A genetic approach to understanding tumor angiogenesis. Cold Spring Harb Symp Quant Biol 2002; 67:249.</a></li><li><a class="nounderline abstract_t">Kastrup O, Maschke M, Diener HC. Pulse-cyclophosphamide in the treatment of ataxic sensory and cranial nerve neuropathy associated with Sjogren's syndrome. Clin Neurol Neurosurg 2005; 107:440.</a></li><li><a class="nounderline abstract_t">Yuan J, Gong L, Wu H, et al. Case report of primary Sjögren Syndrome with simple trigeminal lesion as initial symptom. J Neuroimmunol 2018; 324:126.</a></li><li><a class="nounderline abstract_t">Nascimento IS, Bonfá E, de Carvalho JF, et al. Clues for previously undiagnosed connective tissue disease in patients with trigeminal neuralgia. J Clin Rheumatol 2010; 16:205.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Kaufmann TJ, Keegan BM. Sjogren's syndrome with trigeminal neuropathy: motor involvement. Pract Neurol 2013; 13:340.</a></li><li><a class="nounderline abstract_t">Kaplan JG, Rosenberg R, Reinitz E, et al. Invited review: peripheral neuropathy in Sjogren's syndrome. Muscle Nerve 1990; 13:570.</a></li><li><a class="nounderline abstract_t">Kaltreider HB, Talal N. The neuropathy of Sjögren's syndrome. Trigeminal nerve involvement. Ann Intern Med 1969; 70:751.</a></li><li><a class="nounderline abstract_t">Imrich R, Alevizos I, Bebris L, et al. Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome. Arthritis Rheumatol 2015; 67:1345.</a></li><li><a class="nounderline abstract_t">Gibbons CH, Freeman R. Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. Auton Neurosci 2009; 146:8.</a></li><li><a class="nounderline abstract_t">Chai J, Logigian EL. Neurological manifestations of primary Sjogren's syndrome. Curr Opin Neurol 2010; 23:509.</a></li><li><a class="nounderline abstract_t">Tobón GJ, Pers JO, Devauchelle-Pensec V, Youinou P. Neurological Disorders in Primary Sjögren's Syndrome. Autoimmune Dis 2012; 2012:645967.</a></li><li><a class="nounderline abstract_t">Freeman SR, Sheehan PZ, Thorpe MA, Rutka JA. Ear, nose, and throat manifestations of Sjögren's syndrome: retrospective review of a multidisciplinary clinic. J Otolaryngol 2005; 34:20.</a></li><li><a class="nounderline abstract_t">Tumiati B, Casoli P, Parmeggiani A. Hearing loss in the Sjögren syndrome. Ann Intern Med 1997; 126:450.</a></li><li><a class="nounderline abstract_t">Sivadasan A, Muthusamy K, Patel B, et al. Clinical Spectrum, Therapeutic Outcomes, and Prognostic Predictors in Sjogren's Syndrome-associated Neuropathy. Ann Indian Acad Neurol 2017; 20:278.</a></li><li><a class="nounderline abstract_t">Seeliger T, Prenzler NK, Gingele S, et al. Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren's Syndrome. Front Immunol 2019; 10:1600.</a></li><li><a class="nounderline abstract_t">Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjögren's syndrome. Medicine (Baltimore) 1982; 61:247.</a></li><li><a class="nounderline abstract_t">Massara A, Bonazza S, Castellino G, et al. Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) 2010; 49:1540.</a></li><li><a class="nounderline abstract_t">Akasbi M, Berenguer J, Saiz A, et al. White matter abnormalities in primary Sjögren syndrome. QJM 2012; 105:433.</a></li><li><a class="nounderline abstract_t">Rabadi MH, Kundi S, Brett D, Padmanabhan R. Neurological pictures. Primary Sjögren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010; 81:213.</a></li><li><a class="nounderline abstract_t">Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 2006; 77:290.</a></li><li><a class="nounderline abstract_t">Tang WQ, Wei SH. Primary Sjögren's syndrome related optic neuritis. Int J Ophthalmol 2013; 6:888.</a></li><li><a class="nounderline abstract_t">Sun JY, Liu Z, Zhao P, Liu T. Optic neuritis as an initial presentation of primary Sjögren syndrome: A case report and literature review. Medicine (Baltimore) 2016; 95:e5194.</a></li><li><a class="nounderline abstract_t">Sá MJ. Acute transverse myelitis: a practical reappraisal. Autoimmun Rev 2009; 9:128.</a></li><li><a class="nounderline abstract_t">Kahlenberg JM. Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjögren's syndrome. Semin Arthritis Rheum 2011; 40:343.</a></li><li><a class="nounderline abstract_t">Butryn M, Neumann J, Rolfes L, et al. Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren's Syndrome. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Piccolo G, Tavazzi E, Jarius S, et al. Anti-Ma2/Ta antibodies in a woman with primary lateral sclerosis-like phenotype and Sjögren syndrome. Neurol Sci 2011; 32:915.</a></li><li><a class="nounderline abstract_t">Birnbaum J, Atri NM, Baer AN, et al. Relationship Between Neuromyelitis Optica Spectrum Disorder and Sjögren's Syndrome: Central Nervous System Extraglandular Disease or Unrelated, Co-Occurring Autoimmunity? Arthritis Care Res (Hoboken) 2017; 69:1069.</a></li><li><a class="nounderline abstract_t">Zhong YH, Zhong ZG, Zhou Z, et al. Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjögren's syndrome. Neurol Sci 2017; 38:271.</a></li><li><a class="nounderline abstract_t">Martín-Nares E, Hernandez-Molina G, Fragoso-Loyo H. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. Lupus 2019; 28:1302.</a></li><li><a class="nounderline abstract_t">de Seze J, Devos D, Castelnovo G, et al. The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology 2001; 57:1359.</a></li><li><a class="nounderline abstract_t">Pericot I, Brieva L, Tintoré M, et al. Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. Mult Scler 2003; 9:256.</a></li><li><a class="nounderline abstract_t">Maggi P, Absinta M, Grammatico M, et al. Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol 2018; 83:283.</a></li><li><a class="nounderline abstract_t">Venegas Fanchke P, Sinning M, Miranda M. Primary Sjogren's syndrome presenting as a generalized chorea. Parkinsonism Relat Disord 2005; 11:193.</a></li><li><a class="nounderline abstract_t">Delorme C, Cohen F, Hubsch C, Roze E. Chorea as the initial manifestation of Sjögren syndrome. Pediatr Neurol 2015; 52:647.</a></li><li><a class="nounderline abstract_t">Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261:1.</a></li><li><a class="nounderline abstract_t">Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17:1019.</a></li><li><a class="nounderline abstract_t">Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018; 89:346.</a></li><li><a class="nounderline abstract_t">Caselli RJ, Scheithauer BW, Bowles CA, et al. The treatable dementia of Sjögren's syndrome. Ann Neurol 1991; 30:98.</a></li><li><a class="nounderline abstract_t">Tezcan ME, Kocer EB, Haznedaroglu S, et al. Primary Sjögren's syndrome is associated with significant cognitive dysfunction. Int J Rheum Dis 2016; 19:981.</a></li><li><a class="nounderline abstract_t">Manzo C, Martinez-Suarez E, Kechida M, et al. Cognitive Function in Primary Sjögren's Syndrome: A Systematic Review. Brain Sci 2019; 9.</a></li><li><a class="nounderline abstract_t">Malinow KL, Molina R, Gordon B, et al. Neuropsychiatric dysfunction in primary Sjögren's syndrome. Ann Intern Med 1985; 103:344.</a></li><li><a class="nounderline abstract_t">Blanc F, Longato N, Jung B, et al. Cognitive Dysfunction and Dementia in Primary Sjögren's Syndrome. ISRN Neurol 2013; 2013:501327.</a></li><li><a class="nounderline abstract_t">Koçer B, Tezcan ME, Batur HZ, et al. Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations. Brain Behav 2016; 6:e00586.</a></li><li><a class="nounderline abstract_t">Alexander EL, Alexander GE. Aseptic meningoencephalitis in primary Sjögren's syndrome. Neurology 1983; 33:593.</a></li><li><a class="nounderline abstract_t">Rossi R, Valeria Saddi M. Subacute aseptic meningitis as neurological manifestation of primary Sjögren's syndrome. Clin Neurol Neurosurg 2006; 108:688.</a></li><li><a class="nounderline abstract_t">Ishida K, Uchihara T, Mizusawa H. Recurrent aseptic meningitis: a new CSF complication of Sjogren's syndrome. J Neurol 2007; 254:806.</a></li><li><a class="nounderline abstract_t">Chen SF, Chiu MJ, Su JJ. Rhombencephalitis as an initial manifestation of primary Sjögren's syndrome: a case report and review of the literatures. Acta Neurol Taiwan 2011; 20:35.</a></li><li><a class="nounderline abstract_t">Hirohata M, Yasukawa Y, Ishida C, et al. Reversible cortical lesions in primary Sjögren's syndrome presenting with meningoencephalitis as an initial manifestation. J Neurol Sci 2005; 232:111.</a></li><li><a class="nounderline abstract_t">Moutaouakil F, El Moutawakkil B, El Otmani H, et al. [Aseptic meningoencephalitis in primary Gougerot-Sjögren's syndrome]. Rev Neurol (Paris) 2005; 161:1225.</a></li><li><a class="nounderline abstract_t">Gerraty RP, McKelvie PA, Byrne E. Aseptic meningoencephalitis in primary Sjögren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy. Acta Neurol Scand 1993; 88:309.</a></li><li><a class="nounderline abstract_t">Chevalier K, Noel N, Benoudiba F, et al. Anti-Ma2 antibody encephalitis associated with Sjogren's syndrome. Rev Med Interne 2021; 42:575.</a></li><li><a class="nounderline abstract_t">Li X, Kong R, Liao Q, et al. Case Report: Anti-N-Methyl-D-Aspartate Receptor Encephalitis in an Elderly Patient With Primary Sjögren's Syndrome. Front Neurol 2021; 12:656024.</a></li><li><a class="nounderline abstract_t">Tjensvoll AB, Harboe E, Gøransson LG, et al. Headache in primary Sjøgren's syndrome: a population-based retrospective cohort study. Eur J Neurol 2013; 20:558.</a></li><li><a class="nounderline abstract_t">Gökçay F, Oder G, Celebisoy N, et al. Headache in primary Sjögren's syndrome: a prevalence study. Acta Neurol Scand 2008; 118:189.</a></li><li><a class="nounderline abstract_t">Pal B, Gibson C, Passmore J, et al. A study of headaches and migraine in Sjögren's syndrome and other rheumatic disorders. Ann Rheum Dis 1989; 48:312.</a></li><li><a class="nounderline abstract_t">Zahlane S, Louhab N, El Mellakh M, Kissani N. Anterior horn syndrome: A rare manifestation of primary Sjögren's syndrome. Joint Bone Spine 2016; 83:448.</a></li><li><a class="nounderline abstract_t">Katz JS, Houroupian D, Ross MA. Multisystem neuronal involvement and sicca complex: broadening the spectrum of complications. Muscle Nerve 1999; 22:404.</a></li><li><a class="nounderline abstract_t">Rafai MA, Boulaajaj FZ, Moutawakil F, et al. Neurological manifestations revealing primitive Gougerot-Sjogren syndrome: 9 cases. Joint Bone Spine 2009; 76:139.</a></li></ol></div><div id="topicVersionRevision">Topic 120953 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30627507" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neurological Complications of Sjögren's Syndrome: Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29061239" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neurologic Manifestations of Primary Sjögren Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25369438" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neurologic complications of systemic lupus erythematosus, sjögren syndrome, and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31464676" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The kaleidoscope of neurological manifestations in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2538774" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Peripheral neuropathy in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8265827" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16049042" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649487" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [Central and peripheral neurologic lesions in primary Gougerot-Sjögren syndrome. Clinicopathological study of a case].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2327738" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3024557" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30708209" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neurologic manifestations associated with cryoglobulinemia: A single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625331" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26181553" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Clinical Characteristics of Primary Sjogren's Syndrome With Neuromyelitis Optica Spectrum Disorder in China: A STROBE-Compliant Article.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858405" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antiganglion neuron antibodies correlate with neuropathy in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14598044" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34332492" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Autoantibody against the Rab6A/Rab6B in primary autoimmune cerebellar ataxia associated with Sjogren's syndrome: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26873295" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Insights from the ganglionic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21312189" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10902771" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21358442" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33617165" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neurological Involvement in Patients With Primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28422829" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21651503" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary Sjogren's syndrome: cognitive symptoms, mood, and cognitive performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24465419" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neurological involvement in primary Sjögren syndrome: a focus on central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6638957" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Polymorphous meningitis with atypical mononuclear cells in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190294" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158115" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjogren syndrome: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23982950" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Memory dysfunction in primary Sjögren's syndrome is associated with anti-NR2 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26921255" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Heat shock proteins and chronic fatigue in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33095149" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Primary Sjögren's syndrome: central and peripheral nervous system involvements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035421" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34249008" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Understanding Fatigue in Sjögren's Syndrome: Outcome Measures, Biomarkers and Possible Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27110384" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24176941" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Immunological profiles determine neurological involvement in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11517999" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Neurological complications of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21172862" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Peripheral neuropathies in Sjogren syndrome: a new reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23020902" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8265828" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Is central nervous system involvement a systemic manifestation of primary Sjögren's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3261608" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sjögren's syndrome: a study of its neurological complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2327235" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nervous system manifestations in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609267" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Central nervous system disease in primary Sjogrens syndrome: the role of magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220446" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cerebral white matter hyperintensities are not increased in patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10381047" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cerebral white matter lesions in primary Sjögren's syndrome: a controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254018" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The clinical heterogeneity of immune sensory and autonomic neuropathies with (or without) sicca.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668414" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101831" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Peripheral neuropathy in primary sjogren syndrome: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318209" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15318336" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352002" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Nerve conduction studies in selected peripheral nerve disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15342972" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9109867" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Peripheral neuropathy associated with sicca complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18050172" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186536" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Painful small-fiber neuropathy in Sjogren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20827117" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Peripheral nervous system manifestations of Sjögren syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21926185" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26510559" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22641108" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Small-fibre neuropathies--advances in diagnosis, pathophysiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30221483" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Biopsy-Proven Small-Fiber Neuropathy in Primary Sjögren's Syndrome: Neuropathic Pain Characteristics, Autoantibody Findings, and Histopathologic Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22658898" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Differential, size-dependent sensory neuron involvement in the painful and ataxic forms of primary Sjögren's syndrome-associated neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797167" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Use of a novel high-resolution magnetic resonance neurography protocol to detect abnormal dorsal root Ganglia in Sjögren patients with neuropathic pain: case series of 10 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858457" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26596193" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Diagnosis of small fiber neuropathy: A comparative study of five neurophysiological tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34706972" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Small Fiber Neuropathy Incidence, Prevalence, Longitudinal Impairments, and Disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22190313" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Characterization of non-length-dependent small-fiber sensory neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21584943" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: a national multicentric retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458906" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19168191" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21097829" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The dorsal root ganglion under attack: the acquired sensory ganglionopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561032" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Spinal cord magnetic resonance imaging demonstrates sensory neuronal involvement and clinical severity in neuronopathy associated with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24307005" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The neurology of Sjogren's syndrome and the rheumatology of peripheral neuropathy and myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12578938" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25383230" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intravenous Immunoglobulin and Mycophenolate Mofetil for Long-Standing Sensory Neuronopathy in Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27175675" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sjögren Sensory Neuronopathy (Sjögren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11385268" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2173499" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pure sensory neuropathy in patients with primary Sjögren's syndrome: clinical, immunological, and electromyographic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25196820" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Sensory ganglionopathy with livedoid vasculopathy controlled by immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16967492" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858547" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A genetic approach to understanding tumor angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16023544" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pulse-cyclophosphamide in the treatment of ataxic sensory and cranial nerve neuropathy associated with Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30170790" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Case report of primary Sjögren Syndrome with simple trigeminal lesion as initial symptom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20661065" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clues for previously undiagnosed connective tissue disease in patients with trigeminal neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23703941" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Sjogren's syndrome with trigeminal neuropathy: motor involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2167450" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Invited review: peripheral neuropathy in Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4306127" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The neuropathy of Sjögren's syndrome. Trigeminal nerve involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25622919" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144572" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Antibody titers predict clinical features of autoimmune autonomic ganglionopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20689426" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Neurological manifestations of primary Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474573" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Neurological Disorders in Primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15966471" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ear, nose, and throat manifestations of Sjögren's syndrome: retrospective review of a multidisciplinary clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9072930" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hearing loss in the Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28904462" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical Spectrum, Therapeutic Outcomes, and Prognostic Predictors in Sjogren's Syndrome-associated Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31354737" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6283302" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Neurologic complications of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444860" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156707" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : White matter abnormalities in primary Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145030" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Neurological pictures. Primary Sjögren syndrome presenting as neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484634" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Demyelination in rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24392343" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Primary Sjögren's syndrome related optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27858858" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Optic neuritis as an initial presentation of primary Sjögren syndrome: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389491" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Acute transverse myelitis: a practical reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20655576" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32423153" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21369848" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Anti-Ma2/Ta antibodies in a woman with primary lateral sclerosis-like phenotype and Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27696784" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Relationship Between Neuromyelitis Optica Spectrum Disorder and Sjögren's Syndrome: Central Nervous System Extraglandular Disease or Unrelated, Co-Occurring Autoimmunity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27817092" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566079" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673571" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814172" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29328521" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15823485" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Primary Sjogren's syndrome presenting as a generalized chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25959286" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Chorea as the initial manifestation of Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24272588" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20528913" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : EFNS guidelines on diagnosis and management of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29030418" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929232" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The treatable dementia of Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27455357" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Primary Sjögren's syndrome is associated with significant cognitive dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30991679" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cognitive Function in Primary Sjögren's Syndrome: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2992332" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Neuropsychiatric dysfunction in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24224097" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Cognitive Dysfunction and Dementia in Primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28032007" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6682497" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Aseptic meningoencephalitis in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054750" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Subacute aseptic meningitis as neurological manifestation of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17417743" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Recurrent aseptic meningitis: a new CSF complication of Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21249593" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Rhombencephalitis as an initial manifestation of primary Sjögren's syndrome: a case report and review of the literatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15850591" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Reversible cortical lesions in primary Sjögren's syndrome presenting with meningoencephalitis as an initial manifestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16340919" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : [Aseptic meningoencephalitis in primary Gougerot-Sjögren's syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256579" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Aseptic meningoencephalitis in primary Sjögren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34052049" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Anti-Ma2 antibody encephalitis associated with Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34093403" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Case Report: Anti-N-Methyl-D-Aspartate Receptor Encephalitis in an Elderly Patient With Primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23190440" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Headache in primary Sjøgren's syndrome: a population-based retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355394" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Headache in primary Sjögren's syndrome: a prevalence study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2712611" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A study of headaches and migraine in Sjögren's syndrome and other rheumatic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118221" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Anterior horn syndrome: A rare manifestation of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086903" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Multisystem neuronal involvement and sicca complex: broadening the spectrum of complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217338" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Neurological manifestations revealing primitive Gougerot-Sjogren syndrome: 9 cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
